ReviewCurrent oncology reports2022

Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy.

Kalyan R Chitturi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.